secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytoDyn Inc. (CYDY)
CIK:        0001175680
Form:       8-K
Filed at:   2022-03-30T23:59:59+00:00
Accession:  0001193125-22-090064
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytoDyn appoints Karen J. Brunke, Ph.D. as director effective March 27, 2022
----------------------------------------------------------------------------

- Dr. Brunke fills the vacancy created by Harish Seethamraju's resignation in December 2021.
- She brings over 30 years of biotech experience, currently EVP at Jaguar Health (JAGX).
- Board expects to appoint her to Compensation Committee; compensation per nonemployee director policy.
- No transactions requiring disclosure under Item 404(a) between Dr. Brunke and the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175680/000119312522090064/0001193125-22-090064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175680/000119312522090064/d687103d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-090064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer